232 related articles for article (PubMed ID: 31740521)
21. Strategies to improve repeat fecal occult blood testing cancer screening.
Davis TC; Arnold CL; Bennett CL; Wolf MS; Reynolds C; Liu D; Rademaker A
Cancer Epidemiol Biomarkers Prev; 2014 Jan; 23(1):134-43. PubMed ID: 24192009
[TBL] [Abstract][Full Text] [Related]
22. Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized controlled trial.
Jean-Jacques M; Kaleba EO; Gatta JL; Gracia G; Ryan ER; Choucair BN
Ann Fam Med; 2012; 10(5):412-7. PubMed ID: 22966104
[TBL] [Abstract][Full Text] [Related]
23. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
24. Early detection of colorectal cancer with faecal occult blood test screening.
Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
[TBL] [Abstract][Full Text] [Related]
25. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: Prospective cohort study.
Guo F; Chen C; Schöttker B; Holleczek B; Hoffmeister M; Brenner H
Int J Cancer; 2020 May; 146(9):2423-2432. PubMed ID: 31291471
[TBL] [Abstract][Full Text] [Related]
26. Knowledge and belief of fecal occult blood screening: A systematic review.
Hu LF; Yue QQ; Tang T; Sun YX; Zou JY; Huang YT; Zeng X; Zeng Y
Public Health Nurs; 2023; 40(5):782-789. PubMed ID: 37177843
[TBL] [Abstract][Full Text] [Related]
27. Screening with faecal occult blood test (FOBT) for colorectal cancer: assessment of two methods that attempt to improve compliance.
Ore L; Hagoel L; Lavi I; Rennert G
Eur J Cancer Prev; 2001 Jun; 10(3):251-6. PubMed ID: 11432712
[TBL] [Abstract][Full Text] [Related]
28. Strategies for increasing participation in mail-out colorectal cancer screening programs: a systematic review and meta-analysis.
Goodwin BC; Ireland MJ; March S; Myers L; Crawford-Williams F; Chambers SK; Aitken JF; Dunn J
Syst Rev; 2019 Nov; 8(1):257. PubMed ID: 31685010
[TBL] [Abstract][Full Text] [Related]
29. Ontario's ColonCancerCheck: results from canada's first province-wide colorectal cancer screening program.
Rabeneck L; Tinmouth JM; Paszat LF; Baxter NN; Marrett LD; Ruco A; Lewis N; Gao J
Cancer Epidemiol Biomarkers Prev; 2014 Mar; 23(3):508-15. PubMed ID: 24443406
[TBL] [Abstract][Full Text] [Related]
30. Patient-Refined Messaging for a Mailed Colorectal Cancer Screening Program: Findings from the PROMPT Study.
Coronado GD; Thompson JH; Petrik AF; Nyongesa DB; Leo MC; Castillo M; Younger B; Escaron A; Chen A
J Am Board Fam Med; 2019; 32(3):318-328. PubMed ID: 31068396
[TBL] [Abstract][Full Text] [Related]
31. Is the patient activation measure associated with adherence to colonoscopy after a positive fecal occult blood test result?
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
Isr J Health Policy Res; 2018 Dec; 7(1):74. PubMed ID: 30577883
[TBL] [Abstract][Full Text] [Related]
32. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
33. Behavioural and demographic predictors of adherence to three consecutive faecal occult blood test screening opportunities: a population study.
Duncan A; Turnbull D; Wilson C; Osborne JM; Cole SR; Flight I; Young GP
BMC Public Health; 2014 Mar; 14():238. PubMed ID: 24606951
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of a mailed educational reminder to increase colorectal cancer screening.
Lee JK; Groessl EJ; Ganiats TG; Ho SB
BMC Gastroenterol; 2011 Aug; 11():93. PubMed ID: 21867492
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with adherence to fecal occult blood testing for colorectal cancer screening among adults in the Republic of Korea.
Bae N; Park S; Lim S
Eur J Oncol Nurs; 2014 Feb; 18(1):72-7. PubMed ID: 24183583
[TBL] [Abstract][Full Text] [Related]
36. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
37. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis.
van Rossum LG; van Rijn AF; Verbeek AL; van Oijen MG; Laheij RJ; Fockens P; Jansen JB; Adang EM; Dekker E
Int J Cancer; 2011 Apr; 128(8):1908-17. PubMed ID: 20589677
[TBL] [Abstract][Full Text] [Related]
39. From the bench to public health: population-level implementation intentions in colorectal cancer screening.
Neter E; Stein N; Barnett-Griness O; Rennert G; Hagoel L
Am J Prev Med; 2014 Mar; 46(3):273-80. PubMed ID: 24512866
[TBL] [Abstract][Full Text] [Related]
40. Predictors of adherence to repeat fecal occult blood test in a population-based colorectal cancer screening program.
Pornet C; Denis B; Perrin P; Gendre I; Launoy G
Br J Cancer; 2014 Nov; 111(11):2152-5. PubMed ID: 25314056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
